Educational paper: Connective tissue disorders with vascular involvement: from gene to therapy

Heritable connective tissue diseases comprise a heterogeneous group of multisystemic disorders that are characterized by significant morbidity and mortality. These disorders do not merely result from defects in the amount or structure of one of the components of the extracellular matrix, as the extr...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of pediatrics 2013-08, Vol.172 (8), p.997-1005
Main Authors:	Van Laer, Lut, Proost, Dorien, Loeys, Bart L.
Format:	Article
Language:	eng
Subjects:	Aneurysm, Dissecting - drug therapy Aneurysm, Dissecting - genetics Aneurysm, Dissecting - physiopathology Angiotensin II Type 1 Receptor Blockers - metabolism Angiotensin II Type 1 Receptor Blockers - therapeutic use Aortic Aneurysm, Thoracic - drug therapy Aortic Aneurysm, Thoracic - genetics Aortic Aneurysm, Thoracic - physiopathology Humans Medicine Medicine & Public Health Pediatrics Review Transforming Growth Factor beta - genetics Transforming Growth Factor beta - metabolism
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Heritable connective tissue diseases comprise a heterogeneous group of multisystemic disorders that are characterized by significant morbidity and mortality. These disorders do not merely result from defects in the amount or structure of one of the components of the extracellular matrix, as the extracellular matrix also serves other functions, including sequestration of cytokines, such as transforming growth factor beta (TGFβ). Indeed, disturbed TGFβ signaling was demonstrated in several heritable connective tissue diseases, including syndromic forms such as Marfan or Loeys-Dietz syndrome and non-syndromic presentations of thoracic aortic aneurysm/dissection. Because of these findings, new therapeutic targets have been unveiled, leading to the initiation of large clinical trials with angiotensin II type 1 receptor antagonists that also have an inhibiting effect on TGFβ signaling. Here, we present an overview of the clinical characteristics, the molecular findings, and the therapeutic strategies for the currently known syndromic and non-syndromic forms of thoracic aortic aneurysm/dissection.
ISSN:	0340-6199 1432-1076